David Pépin

2.6k total citations
51 papers, 1.1k citations indexed

About

David Pépin is a scholar working on Public Health, Environmental and Occupational Health, Molecular Biology and Reproductive Medicine. According to data from OpenAlex, David Pépin has authored 51 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Public Health, Environmental and Occupational Health, 24 papers in Molecular Biology and 18 papers in Reproductive Medicine. Recurrent topics in David Pépin's work include Reproductive Biology and Fertility (23 papers), Ovarian function and disorders (13 papers) and Ovarian cancer diagnosis and treatment (8 papers). David Pépin is often cited by papers focused on Reproductive Biology and Fertility (23 papers), Ovarian function and disorders (13 papers) and Ovarian cancer diagnosis and treatment (8 papers). David Pépin collaborates with scholars based in United States, Canada and Italy. David Pépin's co-authors include Patricia K. Donahoe, Hatice D. Saatcioglu, Nicholas Nagykery, Mary E. Sabatini, Dan Wang, Guangping Gao, Motohiro Kano, Barbara C. Vanderhyden, LiHua Zhang and David J. Picketts and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and PLoS ONE.

In The Last Decade

David Pépin

47 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Pépin United States 19 494 411 382 204 167 51 1.1k
Ileana Cuevas United States 17 516 1.0× 237 0.6× 167 0.4× 187 0.9× 120 0.7× 28 971
Sylvie Tondeur France 12 491 1.0× 153 0.4× 162 0.4× 83 0.4× 138 0.8× 25 832
Paul P. Szotek United States 9 667 1.4× 214 0.5× 364 1.0× 614 3.0× 163 1.0× 9 1.3k
Edith Chevret France 18 695 1.4× 159 0.4× 257 0.7× 152 0.7× 191 1.1× 44 1.4k
Kirsi Hämäläinen Finland 17 468 0.9× 115 0.3× 141 0.4× 294 1.4× 211 1.3× 32 1.0k
Katherine W. Muto United States 4 414 0.8× 77 0.2× 282 0.7× 281 1.4× 71 0.4× 6 788
Joanna Budna Poland 15 304 0.6× 321 0.8× 153 0.4× 170 0.8× 89 0.5× 60 737
David Peers United States 8 578 1.2× 91 0.2× 116 0.3× 105 0.5× 124 0.7× 8 816
I.-M. Shih United States 11 343 0.7× 72 0.2× 177 0.5× 182 0.9× 232 1.4× 15 768
Ingrid B.J. Joseph United States 17 565 1.1× 56 0.1× 61 0.2× 315 1.5× 201 1.2× 40 1.2k

Countries citing papers authored by David Pépin

Since Specialization
Citations

This map shows the geographic impact of David Pépin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Pépin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Pépin more than expected).

Fields of papers citing papers by David Pépin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Pépin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Pépin. The network helps show where David Pépin may publish in the future.

Co-authorship network of co-authors of David Pépin

This figure shows the co-authorship network connecting the top 25 collaborators of David Pépin. A scholar is included among the top collaborators of David Pépin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Pépin. David Pépin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Howard, J. A., Richard L. Cate, Nicholas Nagykery, et al.. (2025). A divergent two-domain structure of the anti-Müllerian hormone prodomain. Proceedings of the National Academy of Sciences. 122(3). e2418088122–e2418088122.
2.
Chang, Eun Mi, Maëva Chauvin, A Kashiwagi, et al.. (2025). AMH protects the ovary from doxorubicin by regulating cell fate and the response to DNA damage. Proceedings of the National Academy of Sciences. 122(5). e2414734122–e2414734122.
3.
Jiang, Victoria S., Evelyn Minis, Ngoc Minh Nguyen, et al.. (2024). ANTI-MÜLLERIAN HORMONE TREATMENT REGULATES EARLY CELL-CYCLE GENES IN THE PREIMPLANTATION MOUSE EMBRYO. Fertility and Sterility. 122(4). e341–e342. 1 indexed citations
4.
St‐Jean, Guillaume, Derek Boerboom, Gustavo Zamberlam, et al.. (2024). Lats1 and Lats2 regulate YAP and TAZ activity to control the development of mouse Sertoli cells. The FASEB Journal. 38(9). e23633–e23633. 2 indexed citations
5.
Fang, Yiming, Ji Wang, Subramanyam Dasari, et al.. (2024). Cancer associated fibroblasts serve as an ovarian cancer stem cell niche through noncanonical Wnt5a signaling. npj Precision Oncology. 8(1). 7–7. 23 indexed citations
6.
Chauvin, Maëva & David Pépin. (2024). Abstract A023: Pre-clinical evaluation of the gamma-secretase inhibitor nirogacestat in an adult-type ovarian granulosa cell tumor model. Cancer Research. 84(5_Supplement_2). A023–A023.
7.
Chauvin, Maëva, Marie-Charlotte Meinsohn, Santosh K. Dasari, et al.. (2023). Cancer-associated mesothelial cells are regulated by the anti-Müllerian hormone axis. Cell Reports. 42(7). 112730–112730. 11 indexed citations
8.
Liu, Zong‐Ying, Carmen Torres, David Pépin, et al.. (2022). Chronic superphysiologic AMH promotes premature luteinization of antral follicles in human ovarian xenografts. Science Advances. 8(10). eabi7315–eabi7315. 7 indexed citations
9.
Morris, Mary E., Marie-Charlotte Meinsohn, Maëva Chauvin, et al.. (2022). A single-cell atlas of the cycling murine ovary. eLife. 11. 51 indexed citations
10.
Nagykery, Nicholas, Kelly L. Walton, Craig A. Harrison, et al.. (2021). Structure of AMH bound to AMHR2 provides insight into a unique signaling pair in the TGF-β family. Proceedings of the National Academy of Sciences. 118(26). 32 indexed citations
11.
Sacha, Caitlin R., Irene Souter, Paige L. Williams, et al.. (2021). Urinary phthalate metabolite concentrations are negatively associated with follicular fluid anti-müllerian hormone concentrations in women undergoing fertility treatment. Environment International. 157. 106809–106809. 11 indexed citations
12.
Fang, Min, David Pépin, Patricia K. Donahoe, et al.. (2018). Quantification of Müllerian Inhibiting Substance/Anti-Müllerian Hormone polypeptide by isotope dilution mass spectrometry. Analytical Biochemistry. 560. 50–55. 4 indexed citations
13.
Pépin, David, et al.. (2018). Towards international standardization of immunoassays for Müllerian inhibiting substance/anti-Müllerian hormone. Reproductive BioMedicine Online. 37(5). 631–640. 26 indexed citations
14.
Kano, Motohiro, LiHua Zhang, Hatice D. Saatcioglu, et al.. (2017). AMH/MIS as a contraceptive that protects the ovarian reserve during chemotherapy. Proceedings of the National Academy of Sciences. 114(9). E1688–E1697. 150 indexed citations
15.
Qi, Ruogu, Yongheng Wang, Peter M. Bruno, et al.. (2017). Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer. Nature Communications. 8(1). 2166–2166. 70 indexed citations
16.
Song, Jae Yen, Sang-Il Kim, David Pépin, et al.. (2017). Müllerian inhibiting substance inhibits an ovarian cancer cell line via β-catenin interacting protein deregulation of the Wnt signal pathway. International Journal of Oncology. 50(3). 1022–1028. 12 indexed citations
17.
Horn, Heiko, Lihua Zhang, Caroline Coletti, et al.. (2016). CD44 Splice Variant v8-10 as a Marker of Serous Ovarian Cancer Prognosis. PLoS ONE. 11(6). e0156595–e0156595. 42 indexed citations
18.
Basal, Eati, Carrie Langstraat, Patricia K. Donahoe, et al.. (2016). Patterns of Mullerian Inhibiting Substance Type II and Candidate Type I Receptors in Epithelial Ovarian Cancer†. Current Molecular Medicine. 16(3). 222–231. 6 indexed citations
19.
Pépin, David, et al.. (2011). Kallikreins 5, 6 and 10 Differentially Alter Pathophysiology and Overall Survival in an Ovarian Cancer Xenograft Model. PLoS ONE. 6(11). e26075–e26075. 19 indexed citations
20.
Pépin, David, Barbara C. Vanderhyden, David J. Picketts, & Bruce D. Murphy. (2007). ISWI chromatin remodeling in ovarian somatic and germ cells: revenge of the NURFs. Trends in Endocrinology and Metabolism. 18(5). 215–224. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ileana Cuevas Breakdown of academic impact, for papers by Sylvie Tondeur Breakdown of academic impact, for papers by Paul P. Szotek Breakdown of academic impact, for papers by Edith Chevret Breakdown of academic impact, for papers by Kirsi Hämäläinen Breakdown of academic impact, for papers by Katherine W. Muto Breakdown of academic impact, for papers by Joanna Budna Breakdown of academic impact, for papers by David Peers Breakdown of academic impact, for papers by I.-M. Shih Breakdown of academic impact, for papers by Ingrid B.J. Joseph
Rankless by CCL
2026